Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 7, 2025Journal of Biochemical and Molecular Toxicology

Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities

View Full Paper
Ask AI
Bookmark
Share

Authors

JYJing YangQQQing QiaoNLNa Lin

Discussion

Loading...

Member takes

Overview

Review reveals PROTACs effectively target cancer proteins like KRAS and EGFR, suggesting new therapeutic strategies.

Key Points

  • PROTACs offer a novel method to degrade cancer-initiating proteins, presenting a potential breakthrough in cancer treatment.
  • Preclinical studies show PROTACs can efficiently target mutations in KRAS, EGFR, and ALK, showing promise against resistant cancer forms.
  • This research focuses on the role of the ubiquitin-proteasome system in advancing therapeutic agents via PROTAC technology.
  • Developing safer cancer treatments through PROTACs highlights their significance in overcoming conventional therapy limitations.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/689a0fa0e6551bb0af8d19b9https://doi.org/10.1002/jbt.70427
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions2025
  2. 2Nanotechnology-Based Strategies for Overcoming Clinical Limitations of PROTACs in Cancer Therapy2025
  3. 3PROTACs and Glues: Striking Perspectives for Engineering Cancer Therapy À La Carte2025
  4. 4PROTACs in cancer immunotherapy: a minireview2025 · 1 citations
  5. 5Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment2025